Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MET/VEGFR2 inhibitor Foretinib · 1 trial · 1 indication
After completion of Phase I portion of the study
Assessed from the time of first dose. Results will be analyzed at time of final analysis
After completion of phase I
| Arm | Type | Description |
|---|---|---|
| Erlotinib | ACTIVE_COMPARATOR | - |
| Foretinib plus Erlotinib | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MET/VEGFR2 inhibitor Foretinib | DRUG | PhaseI and Phase II Arm A: Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I. |
| erlotinib hydrochloride | DRUG | erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I. |
| laboratory biomarker analysis | OTHER | Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting all of the following criteria: * Locally advanced or metastatic disease * Failed 1-2 prior chemotherapy regimen * Must be eligible to receive erlotinib therapy (i.e., patients ...
Top 20 of 75 competitors
MET/VEGFR2 inhibitor Foretinib is an investigational small molecule being studied in lung cancer. Specifically, it has been evaluated in locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not responded to previous chemotherapy. It is not yet approved for any indication.
MET/VEGFR2 inhibitor Foretinib targets MET and VEGFR2. It is a small molecule designed to inhibit these receptor tyrosine kinases, which are involved in tumor growth and angiogenesis. This dual targeting approach is being explored in oncology.
MET/VEGFR2 inhibitor Foretinib is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical trial evaluating this agent in lung cancer.
MET/VEGFR2 inhibitor Foretinib is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any regulatory agency. The Phase 1 trial has been completed.
MET/VEGFR2 inhibitor Foretinib has been studied in one completed Phase 1 trial, NCT01068587. This trial evaluated the drug in combination with erlotinib hydrochloride versus erlotinib hydrochloride alone in patients with locally advanced or metastatic NSCLC that had not responded to previous chemotherapy. It enrolled 31 participants in Canada.